Key facts
- It has raised $630K across 1 recorded rounds; the latest was Seed Round ($633K) in May 2025.
- Notable investors include MassChallenge, National Institutes of Health, National Institute on Deafness and Other Communication Disorders.
- Gateway Biotechnology has filed 1 Form D with the SEC, most recently Jun 2025 ($633K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Gateway Biotechnology
Funding rounds
1 roundsAbout Gateway Biotechnology
Developer of therapeutics designed to treat patients with hearing disabilities such as hearing loss and tinnitus. The company offers innovative nasal formulations and advanced gene therapy platforms, enabling individuals with auditory impairments to regain hearing function and improve quality of life.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2011
- Employees
- 8
- Website
- gtwbio.com/
- Ownership
- Privately Held (backing)
Gateway Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gateway Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gateway Biotechnology in its N-PORT filings yet. We sweep new filings monthly.